Tacrolimus Toxicity Associated with Concomitant Metoclopramide Therapy

Pharmacotherapy

Volumn 24, Issue 4, 2004, Pages 532-537

  Prescott Jr , William A ^a   Callahan, Brian L ^a   Park, Jeong M ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Drug interaction; Gastric motility; Metoclopramide; Tacrolimus

Indexed keywords

CIMETIDINE; KETOCONAZOLE; METOCLOPRAMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; RIFAMPICIN; TACROLIMUS;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; LIVER FAILURE; LIVER FUNCTION TEST; LIVER TRANSPLANTATION; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; PRURITUS; STOMACH EMPTYING; STOMACH MOTILITY; VOMITING;

ANTIEMETICS; DRUG INTERACTIONS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; LIVER TRANSPLANTATION; METOCLOPRAMIDE; MIDDLE AGED; NEUROTOXICITY SYNDROMES; TACROLIMUS;

EID: 1842480186     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.24.5.532.33357     Document Type: Article

References (25)

1. Fujisawa Healthcare Inc. Prograf (tacrolimus) prescribing information. Deerfield, IL; 2002.
2. Wadhwa NK, Schroeder TJ, O'Flaherty E, Pesce AJ, Myre SA, First MR. The effect of oral metoclopramide on the absorption of cyclosporine. Transplantation 1987;43:211-13.
3. A. H. Robins Co. Reglan (metoclopramide) prescribing information. Richmond, VA; 2001.
4. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
5. Venkataramanan R, Swaminathan A, Prasad T, et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet 1995;29: 404-30.
6. Kelly PA, Burckart GJ, Venkataramanan R. Tacrolimus: A new immunosuppressive agent. Am J Health-Syst Pharm 1995;52: 1521-35.
7. Winkler M, Ringe B, Baumann J, Loss M, Wonigeit K, Pichlmayr R. Plasma vs whole blood for therapeutic drug monitoring of patients receiving FK506 for immunosuppression. Clin Chem 1994;40:2247-53.
8. Backman L, Nicar M, Levy M, et al. FK506 trough levels in whole blood and plasma in liver transplant recipients. Transplantation 1994;57:519-25.
9. Venkataramanan R, Shaw LM, Sarkozi L, et al. Clinical utility of monitoring tacrolimus blood concentrations in liver transplant patients. J Clin Pharmacol 2001;41:542-51.
10. Winkler M, Jost U, Ringe B, Gubernatis G, Wonigeit K, Pichlmayr R. Association of elevated FK 506 plasma levels with nephrotoxicity in liver-grafted patients. Transplant Proc 1991;23:3153-5.
11. Christians U, Jacobsen W, Benet LZ, Lampen A. Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet 2002;41:813-51.
12. Prasad TN, Stiff DD, Subbotina N, et al. FK 506 (tacrolimus) metabolism by rat liver microsomes and its inhibition by other drugs. Res Commun Chem Pathol Pharmacol 1994;84:35-46.
13. Floren LC, Bekersky I, Benet LZ, et al. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin Pharmacol Ther 1997;62:41-9.
14. Moreno M, Latorre A, Manzanares C, et al. Clinical management of tacrolimus drug interactions in renal transplant patients. Transplant Proc 1999;31:2252-3.
15. Kiuchi T, Tanaka K, Inomata Y, et al. Experience of tacrolimus-based immunosuppression in living-related liver transplantation complicated with graft tuberculosis: interaction with rifampicin and side effects. Transplant Proc 1996;28:3171-2.
16. Chenhsu RY, Loong CC, Chou MH, Lin MF, Yang WC. Renal allograft dysfunction associated with rifampin-tacrolimus interaction. Ann Pharmacother 2000;34:27-31.
17. Hebert MF, Fisher RM, Marsh CL, Dressler D, Bekersky I. Effects of rifampin on tacrolimus pharmacokinetics in healthy volunteers. J Clin Pharmacol 1999;39:91-6.
18. Furlan V, Perello L, Jacquemin E, Debray D, Taburet AM. Interactions between FK506 and rifampicin or erythromycin in pediatric liver recipients. Transplantation 1995;59:1217-18.
19. Undre NA. Pharmacokinetics of tacrolimus-based combination therapies. Nephrol Dial Transplant 2003;18(suppl 1):i12-15.
20. Hashimoto Y, Sasa H, Shimomura M, Inui K. Effects of intestinal and hepatic metabolism on the bioavailability of tacrolimus in rats. Pharm Res 1998;15:1609-13.
21. Undre NA, Stevenson P, Schafer A. Pharmacokinetics of tacrolimus: clinically relevant aspects. Transplant Proc 1999;31(suppl 7A):21S-4.
22. Bekersky I, Dressler D, Mekki QA. Effect of low- and high-fat meals on tacrolimus absorption following 5 mg single oral doses to healthy human subjects. J Clin Pharmacol 2001;41:176-82.
23. Bekersky I, Dressler D, Mekki Q. Effect of time of meal consumption on bioavailability of a single oral 5 mg tacrolimus dose. J Clin Pharmacol 2001;41:289-97.
24. Maes BD, Lemahieu W, Kuypers D, et al. Differential effect of diarrhea on FK506 versus cyclosporine A trough levels and resultant prevention of allograft rejection in renal transplant recipients. Am J Transplant 2002;2:989-92.
25. Iglesias Berengue J, López-Espinosa JA, Ortega-López J, et al. Two- to three-fold increase in blood tacrolimus (FK506) levels during diarrhea in liver-transplanted children. Clin Transplant 2003;17:249-53.